Navigation Links
Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
Date:2/29/2008

Total liabilities 1,530,554 1,834,313

SHAREHOLDERS' EQUITY 1,354,420 1,328,232

TOTAL LIABILITIES & SHAREHOLDERS'

EQUITY $2,884,974 $3,162,545

WARNER CHILCOTT LIMITED

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW

(in thousands of U.S. dollars)

(Unaudited)

Quarter Ended Year Ended

Dec-31-07 Dec-31-06 Dec-31-07 Dec-31-06

CASH FLOWS FROM OPERATING

ACTIVITIES:

Net income / (loss) $19,687 $(8,520) $28,875 $(153,510)

Adjustments to reconcile net

income / (loss) to net cash

provided by operating

activities:

Depreciation 2,892 2,171 10,250 7,177

Amortization of intangible

assets 56,169 68,300 228,330 253,425

Amortization of debt finance

costs 3,280 11,135 13,813 30,154

Stock compensation expense 1,085 1,711 6,115 17,787

Accretion of preferred stock

in subsidiary - - - 26,190

Changes in assets and

liabilities:

Decrease / (increase) in

accounts receivable, prepaid

and other assets 12,742 12,780 1,852 (22,914)

(Increase) / decrease in

inventories (621) (6,955) 12,345 (34,978)

Increase in accounts payable,

accrued expenses & other

liabilities 17,107 1,888 32,430 7,933

(Decrease) / increase in

income taxes and other, net (6,507) (11,581) 5,540 (
'/>"/>

SOURCE Warner Chilcott Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results
2. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
3. Warner Chilcott Announces Earnings Release Date and Conference Call for Third Quarter 2007 Financial Results
4. Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent
5. Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
6. Cepheid Reports Fourth Quarter and Full Year 2007 Results
7. Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results
8. US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
9. Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
10. Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results
11. eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... /PRNewswire/ -- China Cord Blood Corporation (NYSE: CO ) ("CCBC," ... leading provider of cord blood collection, laboratory testing, hematopoietic ... that the Special Committee of the Company,s board of directors ... China ) Limited as its independent financial advisor, ... United States legal counsel and Maples ...
(Date:6/2/2015)... Scotland , June 2, 2015 ... addressing the global antibiotic resistance problem  ... novel class of anti-infectives, to address the major ... it has developed a stable intravenous (IV) formulation ... and resistant Gram-positive hospital-acquired infections.  The intravenous ...
(Date:6/1/2015)... June 1, 2015  Turing Pharmaceuticals AG announced that ... Salinas , MD, MSc,  has joined the company ... Dr. Salinas, who holds a medical degree as ... record of significant accomplishments in the pharmaceutical industry, ... Dr. Salinas has played a leadership role in ...
(Date:6/1/2015)... June 1, 2015 GenomeDx Biosciences ... analysis platform, successfully classified various subtypes of ... of certain biomarkers, including one type associated ... unique genomic signature has potential as a ... chemotherapy in patients with muscle-invasive bladder cancers ...
Breaking Biology Technology:China Cord Blood Corporation's Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal 2China Cord Blood Corporation's Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal 3MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 2MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 3Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4
... Blood ... Expertise, PALO ALTO, Calif., May 29 Pelikan Technologies ... announced the appointment of Dennert (Denny) Ware to its,board of ... of Kinetic Concepts, Inc. (KCI), a global medical,technology company, Mr. ...
... China, May 29 /Xinhua-PRNewswire-FirstCall/ -- China,Biologic Products, Inc. ... of the leading plasma-based pharmaceutical companies in the,People,s ... announced that the,Company has been approved by the ... commence the production of Human Albumin 12.5g/vial (25%,50 ...
... Clarient, Inc.,(Nasdaq: CLRT ), a premier ... oncologists and the pharmaceutical industry,today announced that, effective ... will join Clarient as Senior Vice President and ... years experience as a public,company CFO in life ...
Cached Biology Technology:Pelikan Technologies Appoints Denny Ware to Board of Directors 2Pelikan Technologies Appoints Denny Ware to Board of Directors 3China Biologic Products Announces SFDA Approval for the Production and Sale of Human Albumin 12.5g/vial (25%, 50 ml) 2China Biologic Products Announces SFDA Approval for the Production and Sale of Human Albumin 12.5g/vial (25%, 50 ml) 3Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer 2Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer 3Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer 4Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer 5
(Date:4/27/2015)... OXFORD, Conn. , Apr. 27, 2015 ... "Company"), a biometric authentication company focused on the growing ... will commence shipping to pre-order customers the first week ... pre-orders through the month of May. ... is a significant milestone for the company as Wocket® ...
(Date:4/20/2015)... April 20, 2015 Huntington Memorial Hospital is ... implant a new miniaturized, wireless monitoring sensor to manage ... first and only FDA-approved heart failure monitoring device that ... used by physicians to manage heart failure. ... implanted in the pulmonary artery (PA) during a non-surgical ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... 21 June, 2010 The Editors of the leading ... announce that the third Ahmed Zewail Prize in Molecular Sciences ... University of California, Berkeley, USA, for his outstanding contributions to ... monetary award of $20,000 and will be presented during the ...
... technology university, Nanyang Technological University (NTU), and Israel,s ... today announced a new collaboration to jointly offer ... The NTU-Technion Joint PhD degree programme is a ... Materials Science and Bioengineering. Significantly, the joint PhD ...
... Elsevier announced the launch of PeerChoice, a new pilot ... reviewers now have the freedom to choose which articles they ... and interest, efficiency and effectiveness of the peer review process ... three months, starting in June. PeerChoice reverses ...
Cached Biology News:Elsevier announces the winner of the Ahmed Zewail prize in molecular sciences 2NTU ramps up collaboration with Israel's top university 2NTU ramps up collaboration with Israel's top university 3Elsevier pilots PeerChoice in Chemical Physics Letters 2
StemSep Anti-Phycoertherin Tetrameric Antibody Complexes, 2 mL for labeling 1x10 9 cells. Cross-linking Reagent for StemSep Separations of Cells Labeled with PE-conjugated Antibody....
Printer paper for Model 680 series readers is used with the thermal printers of the Model 680 and Model 680 XR microplate readers. Supplied as 2 rolls....
... cell, wide format, is used for vertical electrophoresis applications. ... and requires 1.2 L of running buffer. It includes ... mm IPG conversion kit, which contains accessories for use ... of IPG clamps, 2 sets of 20 x 20 ...
Includes PROTEAN II xi Basic unit and IPG conversion kit PROTEAN II XL Cell, wide format, Compatible with ReadyStrip IPG Strips 1.0 mm 165-3188 1.5 mm 165-3189 2.0 mm 165-3190...
Biology Products: